| Document |
Document Title |
|
WO/2020/040307A1 |
Provided is an affinity carrier having improved alkali resistance. This immunoglobulin-binding protein contains a mutant polypeptide chain. This affinity carrier includes a solid-phase carrier to which the immunoglobulin-binding protein ...
|
|
WO/2020/041557A1 |
This invention relates to protein-based adhesives that are capable to adhere to a substrate in a dry, wet, moist, or an aqueous environment. Particularly, said adhesives comprise a crosslinking agent and an elastin-like polypeptide (ELP)...
|
|
WO/2020/041799A1 |
Disclosed herein are compositions comprising fixed doses of ETC-1002, ezetimibe, and statin, and methods of treating subjects comprising adminstering fixed doses of ETC-1002, ezetimibe, and statin. Also disclosed herein are methods for a...
|
|
WO/2020/039339A1 |
The present invention relates to a process for purification of non‐glycosylated insulin analogues 5 from a mixture comprising glycosylated and non‐glycosylated proteins by removal of glycosylated proteins. The removal is achieved by ...
|
|
WO/2020/038954A1 |
The disclosure relates to a method for pre-analytical treatment of a serum or plasma sample from a patient suspected of suffering from oxidative stress, the method comprising contacting said sample with one or more microcapsules having a...
|
|
WO/2020/036151A1 |
The purpose of the present invention is to provide a separating material which has excellent liquid permeability when used as a column. This separating material comprises a hydrophilic polymer that includes hydrophobic polymer particles ...
|
|
WO/2020/035716A1 |
The subject matter of the invention is a method for conjugation of free thiol group(s) containing biomolecules, leading to the biomolecular complex formation, comprising a reaction to connect biomolecules using a gold-donor agent in whic...
|
|
WO/2020/034286A1 |
A preparation method of Plecanatide comprises the following steps: 1) sequentially coupling an amino acid at position 16-7 on a solid-phase synthetic resin according to a Fmoc solid-phase synthesis strategy; 2) after removal of the Fmoc ...
|
|
WO/2020/034878A1 |
The present invention provides an OCS (carbonyl sulfide)-mediated approach for solid-phase peptide synthesis using amino acid ionic liquids as both recyclable reactants and reaction media. The coupling reactions required no base and solv...
|
|
WO/2020/036903A1 |
This disclosure provides a novel flush method using a recovery flush technique that minimizes yield losses due to inadequate flushing and prevents or reduces dilution of a target protein during a recovery flush.
|
|
WO/2020/037016A1 |
Methods for the production of high purity recombinant protein such as monoclonal antibodies (mAb) using disulfide bond re-oxidation are provided. In particular, the present disclosure provides methods for converting partial molecules (e....
|
|
WO/2020/035079A1 |
Disclosed are a polypeptide having a cardiovascular and cerebrovascular protection function, a preparation method for the polypeptide, and an application of the polypeptide. The amino acid sequence of the polypeptide having a cardiovascu...
|
|
WO/2020/032622A1 |
The present invention provides a functional peptide having excellent antioxidant activity, the peptide having excellent biocompatibility and significantly better antioxidant activity than conventional GSHs in order to overcome the limita...
|
|
WO/2020/030663A1 |
The present invention provides a new building block for peptide synthesis, which introduces a cleavage site that can be used to generate cleavable fragments subsequent to a peptide sequence.
|
|
WO/2020/032444A1 |
The present invention relates to a method for preparing glycine-thymosin β4 (Gly-Tβ4). The present invention has an excellent effect in that, according to the present invention, a large amount of high-purity Gly-Tβ4 can be obtained wi...
|
|
WO/2020/030099A1 |
A method for purifying active substances in non-human animal amniotic fluid, the method comprising a step of separating a neutral fraction having a molecular weight of 500-1200 Daltons from amniotic fluid. Further provided is an extract,...
|
|
WO/2020/027237A1 |
The purpose of the present invention is to provide a method for producing, at a low cost, a peptide having specific binding capability that can be used for target molecule purification. Specifically, this peptide fusion protein includes ...
|
|
WO/2020/027737A1 |
There is provided a solid-supported hydroxy amino acid or a solid-supported amino alcohol of Formula (I) as defined herein. There is further provided a method of making the solid-supported hydroxy amino acid or the solid-supported amino ...
|
|
WO/2020/023620A1 |
Provided is a chemically modified phage display platform and method of use thereof. More specifically, the present disclosure provides a chemically modified phage display library that incorporates 2-acetylphenylboronic acid (APBA) moieti...
|
|
WO/2020/019813A1 |
Disclosed in the present invention are a polypeptide and an application thereof. A preparation method comprises: modifying oxyntomodulin (OXM), and hybridizing same with a peptide sequence of Exenatide, comprising enabling the polypeptid...
|
|
WO/2020/023566A1 |
Provided herein are methods of separating host cell lipases from a production protein in chromatographic processes and methods of improving polysorbate-80 stability in a production protein formulation by separating host cell lipases from...
|
|
WO/2020/022924A1 |
The present invention relates to medicine and biotechnology and can be used in the pharmaceutical industry. The proposed technical solution is a method of separating and purifying imiglucerase, which is used in long-term enzyme-replaceme...
|
|
WO/2020/019128A1 |
Provided are a compound as shown in formula I and the use of the compound in solid-phase synthesis of a polypeptide drug intermediate containing a peptide chain -Ala-Lys(X)- (X being a Glu-fatty alkyl side chain linked to a Lys side chai...
|
|
WO/2020/018910A1 |
This disclosure pertains to compositions comprising an anti-FcRn antibody, M281. The compositions include the full, intact antibody and size variants thereof that not include two antibody heavy chains and to antibody light chains. Thus, ...
|
|
WO/2020/018732A1 |
A composition for charactering an internalizing antibody is provided. The composition includes an antibody-binding moiety and a detectable agent.
|
|
WO/2020/014888A1 |
An application of sericin peptide in inhibiting browning of fruits and vegetables, comprising: separating sericin in natural silk from fibroin, and retaining the sericin; hydrolyzing the sericin using an enzyme so as to hydrolyze same in...
|
|
WO/2020/017919A1 |
The present invention relates to a novel intermediate used for a physiologically active polypeptide and a method for preparing same. The novel intermediate may be effectively used as an intermediate for the preparation of physiologically...
|
|
WO/2020/016638A1 |
The invention relates to a process of obtaining value-added products from de-oiled rice bran. In particular, the present invention relates to a process of preparing protein, alcohols and silicic acid from de-oiled rice bran. The process ...
|
|
WO/2020/013306A1 |
The purpose of the present invention is to provide a composition which can be used for the improvement, maintenance and/or amelioration of an attention function and/or a judging function. According to the present invention, a composition...
|
|
WO/2020/013527A1 |
The present invention relates to an antimicrobial peptide derivative having enhanced antimicrobial activity, hemolytic stability and stability in blood serum. More specifically, the present invention relates to an antimicrobial peptide d...
|
|
WO/2020/009595A1 |
A method of obtaining a new crystalline form of insulin glargine with a zinc content corresponding to a molar ratio of zinc to insulin of 1:3 is disclosed, with should find applications in making pharmaceutical preparations intended for ...
|
|
WO/2020/010261A1 |
Compositions that include stable peptide deficient MHC class I/chaperone complexes and methods of making and using such complexes are provided. In particular embodiments, such peptide deficient MHC class I/chaperone complexes are used to...
|
|
WO/2020/006630A1 |
A light-inducible intracellular protein aggregation system is described herein, which provides invaluable tools to study the role of protein aggregates in proteinopathies and to screen for novel therapeutic compounds. The system generall...
|
|
WO/2020/007899A1 |
The present invention is in the field of biochemistry. The present invention relates to a method for modifying a polypeptide employing a transpeptidase and polypeptides obtainable by the method of the invention. The present invention fur...
|
|
WO/2020/009594A1 |
A crystalline form of zinc-free insulin glargine and a method for its preparation without the use of phenol are disclosed.
|
|
WO/2020/006922A1 |
Provided is a synthetic peptide sp4 having an amino acid sequence as shown in SEQ ID No. 1. Said synthetic peptide, as the sole active ingredient in an anti-tumor pharmacodynamic test, has an inhibitory effect on both the tumor volume an...
|
|
WO/2020/010004A1 |
The present disclosure is directed towards a method for extracting a target polypeptide, preferably an antibody, from a mixture. This includes contacting the mixture to a hydrophobic interaction chromatography (HIC) apparatus consisting ...
|
|
WO/2020/004583A1 |
The present invention relates to a method for isolating a polypeptide, which comprises: a step wherein a composite body of a polypeptide that is a monoclonal antibody and a ligand is formed by mixing the polypeptide and the ligand in a l...
|
|
WO/2020/005120A1 |
The invention is directed to new enzymes of fungal luciferin biosynthesis, the nucleic acids that encode them, and the use of proteins as enzymes catalyzing the stages of fungal luciferin biosynthesis. The invention also provides the use...
|
|
WO/2020/000555A1 |
The invention belongs to the technical field of pharmaceutical chemistry, in which a method for preparing teriparatide is disclosed. First, peptide sequences 1-16 (fragment A) and peptide sequences 17-34 (fragment B) of teriparatide are ...
|
|
WO/2020/000047A1 |
The present application relates to processes for modifying the distribution of a compound in a solution comprising drawing the solution comprising the compound into an electroseparation syringe comprising a syringe barrel, a plunger and ...
|
|
WO/2020/001493A1 |
Provided is a concentrated and enriched magnetic bead purification instrument, comprising a machine base (10), at least one first stirring sleeve frame (11), at least one second stirring sleeve frame (12), a plurality of reagent containe...
|
|
WO/2020/004980A1 |
The present invention provides a method for preparing a PNA oligomer. More specifically, the present invention can prepare a PNA oligomer which is easily separable from byproducts through a simple and short process by using PNA dimers, P...
|
|
WO/2019/244901A1 |
The present invention addresses the problem of providing a method for detecting the presence or absence of a disease, the risk of development of a disease, the degree of progression of a disease and/or the degree of progression of aging ...
|
|
WO/2019/242010A1 |
Provided is a compound or a salt thereof as a linking chain. The compound or a salt thereof can be loaded onto a solid-phase resin for solid-phase synthesis of a polypeptide drug, thereby improving the synthetic yield of the polypeptide ...
|
|
WO/2019/244961A1 |
Provided is an affinity carrier using a mutant VHH antibody. The affinity carrier comprises a solid phase carrier and an immunoglobulin-binding protein bound to the solid phase carrier, wherein the immunoglobulin-binding protein contains...
|
|
WO/2019/241903A1 |
The Active Pharmaceutical Ingredient (API), Bivalirudin, is a 20 amino acid peptide containing one basic and 5 amino acid residues. With a chemical formula of C98H138N24O33 and a molecular weight of 2180.3 g/mol. Bivalirudin is also know...
|
|
WO/2019/242047A1 |
Disclosed by the present invention are a recombinant spider silk protein series, coding genes thereof, expression and purification methods therefor, and an application of the recombinant spider silk protein series in biological materials...
|
|
WO/2019/241938A1 |
Provided is a Scylla paramamosain antibacterial peptide Sparamosin: an existing method of solid phase chemical synthesis is used to obtain a Sparamosin mature peptide having a purity of more than 95% and a functional domain thereof Spara...
|
|
WO/2019/246153A1 |
This disclosure provides a method of purifying proteins using a combined AEX-CEX chromatography in flow-through mode under an operating condition wherein no automation, engineering control, and/ or in-line adjustment is used between the ...
|
